596095-21-5

Basic information

• Product Name: N,4-DIHYDROXY-3-METHOXY-BENZENE CARBOXIMIDOYL CHLORIDE
• Synonyms: N,4-DIHYDROXY-3-METHOXY-BENZENE CARBOXIMIDOYL CHLORIDE
• CAS NO: 596095-21-5
• Molecular Formula: C₈H₈ClNO₃
• Molecular Weight: 0
• Mol File: 596095-21-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,4-DIHYDROXY-3-METHOXY-BENZENE CARBOXIMIDOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N,4-DIHYDROXY-3-METHOXY-BENZENE CARBOXIMIDOYL CHLORIDE(596095-21-5)
• EPA Substance Registry System: N,4-DIHYDROXY-3-METHOXY-BENZENE CARBOXIMIDOYL CHLORIDE(596095-21-5)

Safety Data

• Hazardous Substances Data: 596095-21-5(Hazardous Substances Data)

Upstream product

• 2874-33-1 vanillin oxime 
• 121-33-5 vanillin 

Downstream Products

• 1352954-42-7 2-(3-(4-hydroxy-3-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)acetic acid 

Relevant articles and documents

Synthesis and biological evaluation of novel isoxazole derivatives from acridone

The present study was carried out in an?attempt to synthesize a new class of potential antibacterial agents. In this context, novel isoxazoles were synthesized and evaluated for their potential antibacterial behavior against four pathogenic bacterial strains. The synthesized compounds exhibited moderate-to-good antibacterial activity against these strains. The highest antibacterial activity was observed against the Escherichia coli strains, particularly for compounds 4a and 4e with phenyl and para-nitrophenyl groups on the isoxazole–acridone skeleton;?they showed promising minimum inhibitory concentration values of 16.88 and 19.01 μg/ml, respectively, compared with the standard drug chloramphenicol (22.41 μg/ml). The synthesized compounds were subjected to in silico docking studies to understand the mode of their interactions with the DNA topoisomerase complex (PDB ID: 3FV5) of E. coli. The molecular docking results showed that compounds 4a–l occupy the active site of DNA topoisomerase (PDB ID: 3FV5), stabilized via hydrogen bonding and hydrophobic interactions, which may be the reason behind their interesting in vitro antibacterial activity.

Synthesis and bio-evaluation of human macrophage migration inhibitory factor inhibitor to develop anti-inflammatory agent

Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine, is involved in the development of an array of inflammatory disorders including rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis and sepsis. The synthesis of MIF-inhibitor is a rationale approach to develop novel anti-inflammatory agent to treat multitude of inflammatory diseases. In this work, we have synthesized and evaluated MIF-inhibitory activity of a series of small molecules containing isoxazoline skeleton. Mode of binding of this inhibitor to human MIF (huMIF) was determined by docking studies. The synthesized molecules inhibit tautomerase activity of huMIF. The anti-inflammatory activity of the most active inhibitor, 4-((3-(4-hydroxy-3- methoxyphenyl)-4, 5-dihydroisoxazol-5-yl) methoxy) benzaldehyde (4b) was evaluated against huMIF-induced inflammation in a cellular model (RAW 264.7 cell). Compound 4b significantly inhibits huMIF-mediated NF-κB translocation to the nucleus, up-regulation of inducible nitric oxide synthase and nitric oxide production in RAW 264.7 cell which are the markers for inflammation. The compound 4b is not cytotoxic as evident from cell viability assay. Hence, the compound 4b has potential to be a novel anti-inflammatory agent.